Please login to the form below

Nichi-Iko

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Nichi-Iko's Japan sales performance.

Roche scores another FDA approval for Xofluza

Roche holds worldwide rights to the drug, excluding Japan and Taiwan, which are retained exclusively by Shionogi.

CHMP says OK to UCB/Amgen’s Evenity for osteoporosis after appeal

UCB and Amgen now say they are hoping for an EMA approval before the end of the year, which will come after approvals for Evenity in the US and Japan earlier

Takeda offloads select portfolio to Acino ahead of Shire takeover

However, Takeda maintained that Shire will help it grow outside Japan, and increase the company’s pipeline in the process.

Gilead promotes Andrew Dickinson to CFO, increased M&A expected

The drug is already under review in Europe and Japan, with plans to file in the US soon.

Roche’s MabThera beats incumbent drug in pemphigus vulgaris phase 3

The decline in Japan was steeper still. Falling sales in Europe and Japan were offset by a stronger performance in the US, where sales grew 4%.

1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]

Data provided by GlobalData

GlobalData is the premier source of research and consulting solutions for the pharmaceutical and medical device industries. With the combined expertise of more than 600 researchers, market analysts and consultants, we deliver high-quality, accurate and transparent industry insight that helps our clients to achieve growth and increase business value.

To find out more about how our research and consulting solutions can help you, please visit healthcare.globaldata.com

For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE's Top Pharma List - Methodology